Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Charcot-Marie-Tooth disease, type 4J (CMT4J) belongs to the genetically heterogeneous group of CMT peripheral sensorimotor polyneuropathy diseases.
Features include sometimes findings: Motor delay. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 4 | Distal arthrogryposis, Distal muscle weakness, Ankle flexion contracture |
Brain and nerves | 2 | Hyporeflexia, Difficulty walking (gait disturbance) |
FIG4 encodes FIG4 phosphoinositide 5-phosphatase (907 aa). Dual specificity phosphatase component of the PI(3,5)P2 regulatory complex which regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Highest expression in Artery Tibial (25.0 TPM) and Brain Frontal Cortex BA9 (22.9 TPM).
Charcot-Marie-Tooth disease type 4J is associated with mutations in the FIG4 gene on chromosome 6.
FIG4 is classified as a druggable target with score 0.0.
Genetic testing for FIG4 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for Charcot-Marie-Tooth disease type 4J. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for Charcot-Marie-Tooth disease type 4J, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Charcot-Marie-Tooth disease type 4J. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
AAV9 gene therapy containing codon optimized human FIG4 cDNA coding sequence | AAV9 gene therapy containing codon optimized human FIG4 cDNA coding sequence | Elpida Therapeutics | 2024 | — | Designated |
2 trials found
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions and gene therapy. Pipeline includes 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
4 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 4J. Research spans Review / Meta-Analysis (50%), Case Report / Case Series (25%), and Epidemiology / Natural History (25%).
Prasun P (2026). [PMID: 42170697](https://pubmed.ncbi.nlm.nih.gov/42170697/). *Clin Genet*. [Case Report / Case Series]
Lauerova B (2025). [PMID: 41177402](https://pubmed.ncbi.nlm.nih.gov/41177402/). *Eur J Med Genet*. [Review / Meta-Analysis]
Sadjadi R (2024). [PMID: 39133880](https://pubmed.ncbi.nlm.nih.gov/39133880/). *Neurology*. [Epidemiology / Natural History]
Boura I (2024). [PMID: 39457468](https://pubmed.ncbi.nlm.nih.gov/39457468/). *Genes (Basel)*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 3:07 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 4J
AI-curated news mentioning Charcot-Marie-Tooth disease type 4J
Updated May 6, 2026
A study details clinical and pathological findings in two Italian siblings of Romani ancestry diagnosed with Charcot-Marie-Tooth type 4D. This research contributes to the understanding of the disease's genetic and phenotypic variability.
A new study provides insights into the genetic and nerve imaging characteristics of Charcot-Marie-Tooth disease type 4F. This research enhances understanding of the disease's pathology and could inform future therapeutic strategies.
A recent German survey study sheds light on the patient journey for those with Charcot-Marie-Tooth Disease, highlighting key challenges and experiences faced by patients. This research contributes valuable insights into the lived experiences of individuals affected by this rare neurological disorder.